Literature DB >> 26092877

Point/Counterpoint: Stereotactic radiosurgery without whole-brain radiation for patients with a limited number of brain metastases: the current standard of care?

Arjun Sahgal1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26092877      PMCID： PMC5762010          DOI： 10.1093/neuonc/nov087

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  15 in total

1.  Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.

Authors:  Hidefumi Aoyama; Hiroki Shirato; Masao Tago; Keiichi Nakagawa; Tatsuya Toyoda; Kazuo Hatano; Masahiro Kenjyo; Natsuo Oya; Saeko Hirota; Hiroki Shioura; Etsuo Kunieda; Taisuke Inomata; Kazushige Hayakawa; Norio Katoh; Gen Kobashi
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

2.  Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study.

Authors:  Martin Kocher; Riccardo Soffietti; Ufuk Abacioglu; Salvador Villà; Francois Fauchon; Brigitta G Baumert; Laura Fariselli; Tzahala Tzuk-Shina; Rolf-Dieter Kortmann; Christian Carrie; Mohamed Ben Hassel; Mauri Kouri; Egils Valeinis; Dirk van den Berge; Sandra Collette; Laurence Collette; Rolf-Peter Mueller
Journal:  J Clin Oncol       Date:  2010-11-01       Impact factor: 44.544

3.  A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases.

Authors:  May Tsao; Wei Xu; Arjun Sahgal
Journal:  Cancer       Date:  2011-09-01       Impact factor: 6.860

4.  Stereotactic radiosurgery alone for brain metastases.

Authors:  Arjun Sahgal; David Larson; Jonathan Knisely
Journal:  Lancet Oncol       Date:  2015-03       Impact factor: 41.316

5.  Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial.

Authors:  Vinai Gondi; Stephanie L Pugh; Wolfgang A Tome; Chip Caine; Ben Corn; Andrew Kanner; Howard Rowley; Vijayananda Kundapur; Albert DeNittis; Jeffrey N Greenspoon; Andre A Konski; Glenn S Bauman; Sunjay Shah; Wenyin Shi; Merideth Wendland; Lisa Kachnic; Minesh P Mehta
Journal:  J Clin Oncol       Date:  2014-10-27       Impact factor: 44.544

6.  Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.

Authors:  Paul D Brown; Stephanie Pugh; Nadia N Laack; Jeffrey S Wefel; Deepak Khuntia; Christina Meyers; Ali Choucair; Sherry Fox; John H Suh; David Roberge; Vivek Kavadi; Soren M Bentzen; Minesh P Mehta; Deborah Watkins-Bruner
Journal:  Neuro Oncol       Date:  2013-08-16       Impact factor: 12.300

7.  Cost-effectiveness of stereotactic radiosurgery with and without whole-brain radiotherapy for the treatment of newly diagnosed brain metastases.

Authors:  Matthew D Hall; James L McGee; Mackenzie C McGee; Kevin A Hall; David M Neils; Jeffrey D Klopfenstein; Patrick W Elwood
Journal:  J Neurosurg       Date:  2014-12       Impact factor: 5.115

8.  Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis.

Authors:  Alexander Sun; Kyounghwa Bae; Elizabeth M Gore; Benjamin Movsas; Stuart J Wong; Christina A Meyers; James A Bonner; Steven E Schild; Laurie E Gaspar; Jeffery A Bogart; Maria Werner-Wasik; Hak Choy
Journal:  J Clin Oncol       Date:  2010-12-06       Impact factor: 44.544

9.  Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.

Authors:  David W Andrews; Charles B Scott; Paul W Sperduto; Adam E Flanders; Laurie E Gaspar; Michael C Schell; Maria Werner-Wasik; William Demas; Janice Ryu; Jean-Paul Bahary; Luis Souhami; Marvin Rotman; Minesh P Mehta; Walter J Curran
Journal:  Lancet       Date:  2004-05-22       Impact factor: 79.321

10.  Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.

Authors:  Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers
Journal:  Lancet Oncol       Date:  2009-10-02       Impact factor: 41.316
View more
  5 in total

1.  The rapidly evolving treatment landscape for patients with brain metastases from epidermal growth factor receptor mutated non-small cell lung cancer.

Authors:  Anthony M Brade
Journal:  Transl Lung Cancer Res       Date:  2017-12

2.  The predictive capacity of apparent diffusion coefficient (ADC) in response assessment of brain metastases following radiation.

Authors:  Raphael Jakubovic; Stephanie Zhou; Chris Heyn; Hany Soliman; Liyang Zhang; Richard Aviv; Arjun Sahgal
Journal:  Clin Exp Metastasis       Date:  2016-01-19       Impact factor: 5.150

3.  ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.

Authors:  Debu Tripathy; Sara M Tolaney; Andrew D Seidman; Carey K Anders; Nuhad Ibrahim; Hope S Rugo; Chris Twelves; Veronique Dieras; Volkmar Müller; Mary Tagliaferri; Alison L Hannah; Javier Cortés
Journal:  Future Oncol       Date:  2019-05-10       Impact factor: 3.404

Review 4.  Stereotactic radiosurgery alone for multiple brain metastases? A review of clinical and technical issues.

Authors:  Arjun Sahgal; Mark Ruschin; Lijun Ma; Wilko Verbakel; David Larson; Paul D Brown
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

Review 5.  Updates in the management of brain metastases.

Authors:  Nils D Arvold; Eudocia Q Lee; Minesh P Mehta; Kim Margolin; Brian M Alexander; Nancy U Lin; Carey K Anders; Riccardo Soffietti; D Ross Camidge; Michael A Vogelbaum; Ian F Dunn; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2016-08       Impact factor: 12.300
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.